1259TiP A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i).
Authors
Gasal, EArance Fernandez, A
Ascierto, P
Atkinson, V
Dummer, R
Flaherty, K
Grob, J
Hansson, J
Hassel, J
Larkin, J
Lebbé, C
Long, G
Lorigan, Paul C
Miller, W
Nathan, P
Ribas, A
Robert, C
Schadendorf, D
Tawbi, H
Upalawanna, A
Affiliation
Medical Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJIssue Date
2017-09
Metadata
Show full item recordCitation
1259TiP A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i). 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx377.044Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx377.044/4109331/1259TiPA-randomized-doubleblind-placebocontrolledType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx377.044